|
110 Companies |
|
139 Products |
|
139 Products |
|
95 Mechanisms of Action |
|
2 Trials |
|
919 News |
|
| «12...78910111213141516171819» |
- ||||| Enbrel (etanercept) / Pfizer, Amgen
New P4 trial: Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab (clinicaltrials.gov) - Feb 29, 2012
P4, N=100, Recruiting, Sponsor: Amgen
- Enrollment open: MMAPPS: Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study (clinicaltrials.gov) - Feb 22, 2012
P=N/A, N=50, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting
- | Cosentyx (secukinumab) / Novartis
Biomarker, New P2 trial: Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients (clinicaltrials.gov) - Feb 21, 2012
P2, N=36, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- | BCT 194 / Novartis
New P1 trial: Pharmacokinetics and Pharmacodynamics of BCT194 in Psoriatic Patients (clinicaltrials.gov) - Feb 21, 2012
P1, N=12, Completed, Sponsor: Novartis Pharmaceuticals
- ||||| Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
New P2 trial: LEO 90100 in the Treatment of Psoriasis Vulgaris (clinicaltrials.gov) - Feb 20, 2012
P2, N=303, Completed, Sponsor: LEO Pharma
- ||||| Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
New P2 trial: LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris (clinicaltrials.gov) - Feb 20, 2012
P2, N=376, Completed, Sponsor: LEO Pharma
- | GSK 2245840 / GSK
Trial completion: Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis (clinicaltrials.gov) - Feb 15, 2012
P2a, N=40, Completed, Sponsor: Sirtris, a GSK Company
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| Trial completion: PREPARE: Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice (clinicaltrials.gov) - Feb 14, 2012
P4, N=1013, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || calcipotriol/betamethasone dipropionate / Generic mfg.
Enrollment change: Efficacy, Tolerability and Handling of Daivobet (clinicaltrials.gov) - Feb 8, 2012
P=N/A, N=588, Completed, Sponsor: LEO Pharma
Active, not recruiting --> Completed N=750 --> 588
- ||| calcipotriol/betamethasone dipropionate / Generic mfg.
Trial completion: Efficacy, Tolerability and Handling of Daivobet (clinicaltrials.gov) - Feb 8, 2012
P=N/A, N=588, Completed, Sponsor: LEO Pharma
N=750 --> 588 Not yet recruiting --> Completed
- ||| dimethyl fumarate controlled release (FP 187) / Forward Pharma
Enrollment change: Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Feb 6, 2012
P2, N=252, Completed, Sponsor: Forward-Pharma GmbH
Not yet recruiting --> Completed N=180 --> 252
- | atorvastatin / Generic mfg.
Trial initiation date: Influence of Atorvastatin on Psoriasis Severity and Endothelial Function (clinicaltrials.gov) - Feb 2, 2012
P3, N=110, Not yet recruiting, Sponsor: shmuel fuchs
N=180 --> 252 Initiation date: Feb 2012 --> Aug 2012
- |||||||||| Xeljanz (tofacitinib) / Pfizer
Clinical: A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis (clinicaltrials.gov) - Jan 24, 2012
P3, N=95, Completed, Sponsor: Pfizer
- ||||||| desoximetasone topical spray / Generic mfg.
Trial completion: Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Jan 18, 2012
P3, N=120, Completed, Sponsor: Taro Pharmaceuticals USA
Initiation date: Feb 2012 --> Aug 2012 Recruiting --> Completed
- ||||||| desoximetasone topical spray / Generic mfg.
Trial completion: Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Jan 18, 2012
P3, N=120, Completed, Sponsor: Taro Pharmaceuticals USA
Recruiting --> Completed Recruiting --> Completed
- |||| desoximetasone topical spray / Generic mfg.
Trial completion: Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study (clinicaltrials.gov) - Jan 18, 2012
P2, N=151, Completed, Sponsor: Taro Pharmaceuticals USA
Recruiting --> Completed Active, not recruiting --> Completed
- Raptiva (efalizumab) / Roche, EMD Serono, Xoma
Trial termination: Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis (clinicaltrials.gov) - Jan 17, 2012
P4, N=96, Terminated, Sponsor: Norwegian University of Science and Technology
Active, not recruiting --> Completed Recruiting --> Terminated; efalizumab was withdrawn from market; full 2 years follow-up only 14 patients
- Raptiva (efalizumab) / Roche, EMD Serono, Xoma
Enrollment change: Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis (clinicaltrials.gov) - Jan 17, 2012
P4, N=96, Terminated, Sponsor: Norwegian University of Science and Technology
Recruiting --> Terminated; efalizumab was withdrawn from market; full 2 years follow-up only 14 patients N=148 --> 96
- | Ultravate (halobetasol proprionate) / Sun Pharma
Trial completion: Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis (clinicaltrials.gov) - Jan 16, 2012
P2, N=43, Completed, Sponsor: Therapeutics, Inc.
N=148 --> 96 Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment change: Rituxan With or Without Methotrexate in Psoriatic Arthritis (clinicaltrials.gov) - Jan 16, 2012
P1, N=6, Completed, Sponsor: Swedish Medical Center
Active, not recruiting --> Completed N=20 --> 6
- Stelara (ustekinumab) / J&J
New P4 trial, HEOR: The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment (clinicaltrials.gov) - Jan 16, 2012
P4, N=35, Recruiting, Sponsor: University of California, San Francisco
- AMG 811 / Amgen
New P1 trial: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis (clinicaltrials.gov) - Jan 16, 2012
P1, N=9, Completed, Sponsor: Amgen
- | Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Pfizer, Amgen
Biomarker, Trial completion: A Study to Assess the Effect of Ustekinumab (Stelara (clinicaltrials.gov) - Jan 16, 2012
P1, N=40, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=20 --> 6 Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Rituxan With or Without Methotrexate in Psoriatic Arthritis (clinicaltrials.gov) - Jan 16, 2012
P1, N=6, Completed, Sponsor: Swedish Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || atorvastatin / Generic mfg.
New P3 trial: Influence of Atorvastatin on Psoriasis Severity and Endothelial Function (clinicaltrials.gov) - Jan 14, 2012
P3, N=110, Not yet recruiting, Sponsor: shmuel fuchs
- | Amevive (alefacept) / Astellas
Enrollment change: Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis (clinicaltrials.gov) - Jan 5, 2012
P2, N=30, Completed, Sponsor: Astellas Pharma Inc
Active, not recruiting --> Completed N=50 --> 30
- Amevive (alefacept) / Astellas
Clinical data, Trial completion: Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis (clinicaltrials.gov) - Jan 5, 2012
P=N/A, N=18, Completed, Sponsor: University of California, San Francisco
N=50 --> 30 Active, not recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open: Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities (clinicaltrials.gov) - Dec 27, 2011
P=N/A, N=266, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Stelara (ustekinumab) / J&J
Trial completion: TRANSIT: A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate (clinicaltrials.gov) - Dec 21, 2011
P4, N=490, Completed, Sponsor: Janssen-Cilag International NV
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
Clinical data, Trial completion, Compliance: EviraEAST: EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries (clinicaltrials.gov) - Dec 19, 2011
P=N/A, N=809, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Ozespa (briakinumab) / AbbVie
Trial completion: Open Label Continuation Study in Moderate to Severe Psoriasis (clinicaltrials.gov) - Dec 19, 2011
P3, N=2301, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- prezalumab (AMG 557) / Amgen, AstraZeneca
New P1 trial: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis (clinicaltrials.gov) - Dec 14, 2011
P1, N=6, Terminated, Sponsor: Amgen
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, Compliance: Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care (clinicaltrials.gov) - Dec 12, 2011
P=N/A, N=252, Completed, Sponsor: Abbott
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
New P1 trial: A Clinical Pharmacology of KHK4827 in Healthy Volunteers and Subject With Moderate to Severe Psoriasis (clinicaltrials.gov) - Dec 6, 2011
P1, N=48, Completed, Sponsor: Kyowa Hakko Kirin Company, Limited
- | calcipotriol/betamethasone dipropionate / Generic mfg.
Trial completion: Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris (clinicaltrials.gov) - Dec 5, 2011
P2, N=33, Completed, Sponsor: LEO Pharma
Active, not recruiting --> Completed Recruiting --> Completed
- ||||| Apo805K1 / Apotex
New P2 trial: Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis (clinicaltrials.gov) - Nov 30, 2011
P2, N=60, Completed, Sponsor: ApoPharma
- Tremfya (guselkumab) / J&J
New P1 trial: A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Nov 30, 2011
P1, N=24, Completed, Sponsor: Janssen Pharmaceutical K.K.
- ||||| Tremfya (guselkumab) / J&J
New P2 trial: X-PLORE: A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (clinicaltrials.gov) - Nov 29, 2011
P2, N=293, Active, not recruiting, Sponsor: Janssen Inc.
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial termination: Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315) (clinicaltrials.gov) - Nov 17, 2011
P3, N=39, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed Completed --> Terminated; In Amendment 1 of P05319 [NCT 00779675], the option to enroll into this study, was discontinued due to low numbers of participants with suboptimal response.
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Enrollment change: Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315) (clinicaltrials.gov) - Nov 17, 2011
P3, N=39, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Completed --> Terminated; In Amendment 1 of P05319 [NCT 00779675], the option to enroll into this study, was discontinued due to low numbers of participants with suboptimal response. N=200 --> 39
- | Dovonex (calcipotriol) / LEO Pharma, Novartis
Trial completion: An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris (clinicaltrials.gov) - Nov 17, 2011
P1, N=24, Completed, Sponsor: LEO Pharma
N=200 --> 39 Not yet recruiting --> Completed
- |||| VB-201 / VBL Therap
Trial completion: Study to Assess VB-201 in Patients With Psoriasis (clinicaltrials.gov) - Nov 14, 2011
P2, N=185, Completed, Sponsor: Vascular Biogenics Ltd. operating as VBL Therapeutics
Not yet recruiting --> Completed Active, not recruiting --> Completed
- |||||| pegcantratinib (SNA-120) / Sienna
New P2b trial: Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris (clinicaltrials.gov) - Nov 2, 2011
P2b, N=160, Completed, Sponsor: Creabilis SA
- ||| Trial completion: A Study of Effectiveness and Safety of Tumor Necrosis Factor (TNF) Inhibitors in Patients With Moderate to Severe Psoriasis (clinicaltrials.gov) - Oct 31, 2011
P=N/A, N=103, Completed, Sponsor: Abbott
Active, not recruiting --> Completed Recruiting --> Completed
- ||||| New P2 trial: Web-based Support to Manage Arthritis Pain (clinicaltrials.gov) - Oct 30, 2011
P2, N=228, Completed, Sponsor: Inflexxion, Inc.
- Clinical: A Survey on the Role and Benefits of Online Social Networks on Filipino Patients With Psoriasis (clinicaltrials.gov) - Oct 25, 2011
P=N/A, N=124, Completed, Sponsor: University of the Philippines
- | Dovonex (calcipotriol) / LEO Pharma, Novartis
New P1 trial: An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris (clinicaltrials.gov) - Oct 25, 2011
P1, N=24, Completed, Sponsor: LEO Pharma
- |||| Eucrisa (crisaborole) / Pfizer
Trial completion: AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis (clinicaltrials.gov) - Oct 24, 2011
P2, N=68, Completed, Sponsor: Anacor Pharmaceuticals, Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- |||| calcipotriol/betamethasone dipropionate / Generic mfg.
Trial completion: Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris (clinicaltrials.gov) - Oct 23, 2011
P2, N=102, Completed, Sponsor: LEO Pharma
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Tzield (teplizumab) / Provention Bio
Trial termination: PsA Treatment With hOKT3γ1 (Ala-Ala) (clinicaltrials.gov) - Oct 20, 2011
P2, N=4, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Suspended --> Terminated; Study team decision-impact(s) of change in hOKT3γ1 (Ala-Ala) manufacturer during study.